IPP Bureau
Merck’s KEYTRUDA & WELIREG combo shows breakthrough results in kidney cancer trial
By IPP Bureau - March 03, 2026
Merck emphasized the broader significance of the findings
AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients
By IPP Bureau - March 03, 2026
This study evaluated a difficult-to-treat Crohn's disease patient population
Bioxytran reports 90% day-5 viral clearance in COVID-19 trial at highest dose of ProLectin-M
By IPP Bureau - March 03, 2026
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
Medi Assist teams up with LawtonAsia to bring AI-powered health-tech to Southeast Asia
By IPP Bureau - March 03, 2026
The collaboration will leverage Medi Assist’s proprietary technology to streamline claims processing, enhance transparency, and deliver smarter health benefits to policyholders in the region
Dabur backs luxury skincare startup RAS Beauty with Rs 60 crore investment
By IPP Bureau - March 03, 2026
The company has shown remarkable growth, posting a three-year CAGR of around 75% with an ARR of roughly Rs 100 crore and impressive gross margins
FDA nod to YUVIWEL, first once-weekly treatment for kids with achondroplasia
By IPP Bureau - March 03, 2026
Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications
Caplin Steriles gets FDA approval for desmopressin
By IPP Bureau - March 02, 2026
Desmopressin Acetate Injection is primarily used to treat central diabetes insipidus, haemophilia A, and von Willebrand disease
Zydus receives final approvals from USFDA for Ivermectin Tablets USP
By IPP Bureau - March 02, 2026
Ivermectin Tablets USP, 3 mg, are prescription anti-parasitic medications primarily indicated for treating parasitic worm infections in humans
Moderna wins EU backing for world’s first combined flu-COVID shot
By IPP Bureau - March 02, 2026
The decision marks a pivotal moment for the Massachusetts-based biotech giant
Iza-bren delivers dual survival win in phase III trial for hard-to-treat breast cancer
By IPP Bureau - March 02, 2026
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
IRLAB Therapeutics doses first patient in pivotal apathy trial
By IPP Bureau - March 02, 2026
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
Chennai gets first structured geriatric continuity-of-care programme
By IPP Bureau - March 02, 2026
Swayam is designed to support elderly patients and their families with seamless access to coordinated medical care
SEOPRO stuns pharma leaders with AI-driven portfolio management at EBMPPPM 2026
By IPP Bureau - March 02, 2026
During live demonstrations, industry leaders highlighted SEOPRO’s ability to spot portfolio risk, execution bottlenecks, and decision delays early—before they escalate into costly program disruptions
